美股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

Baillie Gifford International Alpha ETF

25.23

+0.01060.04%

成交量：8

成交额：201

市值：3.28亿

市盈率：- -

高：25.23

开：25.22

低：25.23

收：25.22

52周最高：25.97

52周最低：23.97

股本：1,301.20万

流通股本：1,301.20万

量比：0.00

换手率：0.00%

股息：- -

股息率：- -

净资产收益率：--

总资产收益率：--

市净率：--

市盈率(LYR):- -

数据加载中...

总览公司新闻资讯公告

诺和诺德首席执行官称，公司资产负债表可支撑更大规模交易。

朗格表示，诺和诺德同时在疼痛与成瘾领域探索新方向。

注射明星减肥药或导致失明？礼来和诺和诺德两巨头在美遭患者起诉

注射明星减肥药或导致失明？礼来和诺和诺德两巨头在美遭患者起诉

诺和诺德首席科学官：我们预计截至今年年底将至少有五款口服候选药物处于临床开发阶段。

诺和诺德首席执行官：到2030年，我们将为全球超过6000万患者提供服务。

诺和诺德首席执行官：到2030年，我们将为全球逾6000万患者提供服务。

诺和诺德CEO表示，将在失去独家专利权之前，就推出新款糖尿病和肥胖症创新药物。

诺和诺德首席执行官：我们将在专利独占期到期前推出下一拨糖尿病与肥胖症创新产品。

诺和诺德首席执行官：到2030年，我们的产能将能够满足500万名Wegovy口服版使用者的用药需求。

诺和诺德首席执行官称，2035年管线产品销售目标已计入风险调整。

诺和诺德(NVO.US)CEO：将加强糖尿病治疗业务；正在创建一个新的领域，为血液和内分泌。

诺和诺德首席执行官：尽管近期遭遇挫折，心血管领域仍是我们显而易见的下一拓展方向。

诺和诺德展望未来重磅新药上市，投资者反应不及预期

诺和诺德首席执行官表示，公司正将裁员释放的资金投入研发部门。

诺和诺德首席执行官：我们将强化糖尿病照护业务。

诺和诺德美股盘前跌近7%

诺和诺德(NVO.US)CEO：到目前为止，美国使用Wegovy药片的处方已达700万份。

诺和诺德首席执行官：维戈维口服药处方量已达700万张。

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/hans/stock/BGIA/news?page=10"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BGIA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BGIA\",,,,,undefined,":{"symbol":"BGIA","market":"US","secType":"STK","nameCN":"Baillie Gifford International Alpha ETF","latestPrice":25.2294,"timestamp":1791921600000,"preClose":25.2188,"halted":0,"volume":8,"delay":0,"changeRate":0.00042032134756596714,"floatShares":13012033,"shares":13012033,"eps":0,"marketStatus":"未开盘","change":0.0106,"latestTime":"10-13 16:00:00 EDT","open":25.2188,"high":25.2294,"low":25.2294,"amount":201,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1791964800000},"marketStatusCode":0,"adr":0,"exchange":"NASDAQ","adjPreClose":25.2188,"bidAskSpread":0,"volumeRatio":0.002641},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BGIA\",,,,,undefined,":{"symbol":"BGIA","floatShares":13012033,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.002641,"shares":13012033,"dividePrice":0,"high":25.2294,"amplitude":0,"preClose":25.2188,"low":25.2294,"week52Low":23.9707,"pbRate":"--","week52High":25.97,"institutionHeld":0,"latestPrice":25.2294,"eps":0,"divideRate":0,"volume":8,"delay":0,"ttmEps":0,"open":25.2188,"prevYearClose":25.2,"prevWeekClose":25.3417,"prevMonthClose":24.9683,"prevQuarterClose":24.9683,"fiveDayClose":25.4651,"twentyDayClose":24.9961,"sixtyDayClose":24.2745},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BGIA\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BGIA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BGIA\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BGIA\",pageSize:20,pageCount:10,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2669315117","title":"诺和诺德首席执行官称，公司资产负债表可支撑更大规模交易。","url":"https://stock-news.laohu8.com/highlight/detail?id=2669315117","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669315117?lang=zh_cn&edition=fundamental","pubTime":"2026-09-21 17:18","pubTimestamp":1789982321,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4585","BK4588","BGIA","SPHQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669151679","title":"朗格表示，诺和诺德同时在疼痛与成瘾领域探索新方向。","url":"https://stock-news.laohu8.com/highlight/detail?id=2669151679","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669151679?lang=zh_cn&edition=fundamental","pubTime":"2026-09-21 17:11","pubTimestamp":1789981896,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BGIA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669759159","title":"注射明星减肥药或导致失明？礼来和诺和诺德两巨头在美遭患者起诉","url":"https://stock-news.laohu8.com/highlight/detail?id=2669759159","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669759159?lang=zh_cn&edition=fundamental","pubTime":"2026-09-21 16:54","pubTimestamp":1789980888,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["CURE","MEDI","PINK","PJP","TRUH","NVOH","NVOC","NVOX","THNR","BGIA","NBDS","FHLC","XLVI","IYH","RSPH","FXH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669590351","title":"注射明星减肥药或导致失明？礼来和诺和诺德两巨头在美遭患者起诉","url":"https://stock-news.laohu8.com/highlight/detail?id=2669590351","media":"澎湃新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669590351?lang=zh_cn&edition=fundamental","pubTime":"2026-09-21 16:53","pubTimestamp":1789980780,"startTime":"0","endTime":"0","summary":"一起美国的诉讼，让GLP-1药物的安全性再次受到行业关注。据外媒报道称，自2025年以来，一律所代表患者在美国新泽西州州法院提起了90多起诉讼，其起诉的对象是明星GLP-1药物司美格鲁肽背后的药企诺和诺德，原因是其在使用降糖版司美格鲁肽之后被诊断为非动脉炎性前部缺血性视神经病变（简称NAION）。上述报道指出，礼来的GLP-1药物替尔泊肽也面临患者针对NAION风险提起的诉讼。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609213880057798.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609213880057798.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["CURE","NVOH","RSPH","PINK","IYH","NVOX","TRUH","FHLC","BGIA","XLVI","NBDS","NVOC","PJP","FXH","MEDI","THNR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669159114","title":"诺和诺德首席科学官：我们预计截至今年年底将至少有五款口服候选药物处于临床开发阶段。","url":"https://stock-news.laohu8.com/highlight/detail?id=2669159114","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669159114?lang=zh_cn&edition=fundamental","pubTime":"2026-09-21 16:47","pubTimestamp":1789980446,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BGIA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669598841","title":"诺和诺德首席执行官：到2030年，我们将为全球超过6000万患者提供服务。","url":"https://stock-news.laohu8.com/highlight/detail?id=2669598841","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669598841?lang=zh_cn&edition=fundamental","pubTime":"2026-09-21 16:34","pubTimestamp":1789979685,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BGIA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669159834","title":"诺和诺德首席执行官：到2030年，我们将为全球逾6000万患者提供服务。","url":"https://stock-news.laohu8.com/highlight/detail?id=2669159834","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669159834?lang=zh_cn&edition=fundamental","pubTime":"2026-09-21 16:34","pubTimestamp":1789979685,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BGIA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669156777","title":"诺和诺德CEO表示，将在失去独家专利权之前，就推出新款糖尿病和肥胖症创新药物。","url":"https://stock-news.laohu8.com/highlight/detail?id=2669156777","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669156777?lang=zh_cn&edition=fundamental","pubTime":"2026-09-21 16:32","pubTimestamp":1789979564,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LNGR","IBBQ","MEDX","BGIA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669156749","title":"诺和诺德首席执行官：我们将在专利独占期到期前推出下一拨糖尿病与肥胖症创新产品。","url":"https://stock-news.laohu8.com/highlight/detail?id=2669156749","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669156749?lang=zh_cn&edition=fundamental","pubTime":"2026-09-21 16:30","pubTimestamp":1789979416,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BGIA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669285156","title":"诺和诺德首席执行官：到2030年，我们的产能将能够满足500万名Wegovy口服版使用者的用药需求。","url":"https://stock-news.laohu8.com/highlight/detail?id=2669285156","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669285156?lang=zh_cn&edition=fundamental","pubTime":"2026-09-21 16:26","pubTimestamp":1789979164,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BGIA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669156444","title":"诺和诺德首席执行官称，2035年管线产品销售目标已计入风险调整。","url":"https://stock-news.laohu8.com/highlight/detail?id=2669156444","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669156444?lang=zh_cn&edition=fundamental","pubTime":"2026-09-21 16:24","pubTimestamp":1789979096,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BGIA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669569731","title":"诺和诺德(NVO.US)CEO：将加强糖尿病治疗业务；正在创建一个新的领域，为血液和内分泌。","url":"https://stock-news.laohu8.com/highlight/detail?id=2669569731","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669569731?lang=zh_cn&edition=fundamental","pubTime":"2026-09-21 16:18","pubTimestamp":1789978738,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BGIA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669115692","title":"诺和诺德首席执行官：尽管近期遭遇挫折，心血管领域仍是我们显而易见的下一拓展方向。","url":"https://stock-news.laohu8.com/highlight/detail?id=2669115692","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669115692?lang=zh_cn&edition=fundamental","pubTime":"2026-09-21 16:18","pubTimestamp":1789978721,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BGIA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669156182","title":"诺和诺德展望未来重磅新药上市，投资者反应不及预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2669156182","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669156182?lang=zh_cn&edition=fundamental","pubTime":"2026-09-21 16:18","pubTimestamp":1789978712,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BGIA","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669815662","title":"诺和诺德首席执行官表示，公司正将裁员释放的资金投入研发部门。","url":"https://stock-news.laohu8.com/highlight/detail?id=2669815662","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669815662?lang=zh_cn&edition=fundamental","pubTime":"2026-09-21 16:17","pubTimestamp":1789978621,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BGIA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669115667","title":"诺和诺德首席执行官：我们将强化糖尿病照护业务。","url":"https://stock-news.laohu8.com/highlight/detail?id=2669115667","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669115667?lang=zh_cn&edition=fundamental","pubTime":"2026-09-21 16:16","pubTimestamp":1789978577,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BGIA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669915621","title":"诺和诺德美股盘前跌近7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2669915621","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669915621?lang=zh_cn&edition=fundamental","pubTime":"2026-09-21 16:15","pubTimestamp":1789978545,"startTime":"0","endTime":"0","summary":"诺和诺德美股盘前跌近7%","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609213880026665.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609213880026665.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BGIA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669156646","title":"诺和诺德(NVO.US)CEO：到目前为止，美国使用Wegovy药片的处方已达700万份。","url":"https://stock-news.laohu8.com/highlight/detail?id=2669156646","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669156646?lang=zh_cn&edition=fundamental","pubTime":"2026-09-21 16:15","pubTimestamp":1789978544,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BGIA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669156653","title":"诺和诺德首席执行官：维戈维口服药处方量已达700万张。","url":"https://stock-news.laohu8.com/highlight/detail?id=2669156653","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669156653?lang=zh_cn&edition=fundamental","pubTime":"2026-09-21 16:14","pubTimestamp":1789978487,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BGIA"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":10,"totalSize":199,"code":"91000000","status":"200"}]}}